Oncolytics Biotech Inc ONC.TO is expected to show no change in quarterly revenue when it reports results on March 7 for the period ending December 31 2024
LSEG's mean analyst estimate for Oncolytics Biotech Inc is for a loss of 12 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Oncolytics Biotech Inc is C$5.67, above its last closing price of $0.65.
Previous quarterly performance (using preferred earnings measure in Canadian dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.10 | -0.10 | -0.12 | Missed | -17.8 |
Jun. 30 2024 | -0.10 | -0.10 | -0.10 | Met | 0.6 |
Mar. 31 2024 | -0.11 | -0.11 | -0.09 | Beat | 16.3 |
Dec. 31 2023 | -0.15 | -0.15 | -0.05 | Beat | 66.1 |
Sep. 30 2023 | -0.10 | -0.10 | -0.14 | Missed | -34.6 |
Jun. 30 2023 | -0.11 | -0.11 | -0.12 | Missed | -6.3 |
Mar. 31 2023 | -0.14 | -0.13 | -0.10 | Beat | 24.5 |
Dec. 31 2022 | -0.09 | -0.10 | -0.15 | Missed | -54.7 |
This summary was machine generated March 5 at 13:34 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。